Corcept Therapeutics Inc
SWB:HTD
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
Corcept Therapeutics Inc
SWB:HTD
|
US |
|
C
|
CVS Health Corp
SWB:CVS
|
US |
|
R
|
R&B Food Supply PCL
SET:RBF
|
TH |
|
C
|
Coca-Cola Co
SWB:CCC3
|
US |
|
Bank of China Ltd
F:W8VS
|
CN |
|
E
|
Eni SpA
BMV:EN
|
IT |
|
T
|
TJX Companies Inc
XMUN:TJX
|
US |
|
Lithium Americas Corp
F:WUC
|
CA |
|
K
|
KGHM Polska Miedz SA
XMUN:KGHA
|
PL |
|
A
|
AeroVironment Inc
F:JPX
|
US |
|
F
|
Ferrari NV
F:2FE
|
IT |
Wall St Price Targets
HTD Price Targets Summary
Corcept Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for HTD is 57.08 EUR with a low forecast of 36.9 EUR and a high forecast of 95.89 EUR.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is HTD's stock price target?
Price Target
57.08
EUR
According to Wall Street analysts, the average 1-year price target for HTD is 57.08 EUR with a low forecast of 36.9 EUR and a high forecast of 95.89 EUR.
What is the Revenue forecast for Corcept Therapeutics Inc?
Projected CAGR
17%
Over the last 13 years, the compound annual growth rate for Revenue has been 52%. The projected CAGR for the next 8 years is 17%.
What is the Operating Income forecast for Corcept Therapeutics Inc?
Projected CAGR
58%
The compound annual growth rate for Operating Income over the next 8 years is 58%.
What is the Net Income forecast for Corcept Therapeutics Inc?
Projected CAGR
36%
The compound annual growth rate for Net Income over the next 8 years is 36%.
